Hypertension in cancer patients treated with anti-angiogenic based regimens

New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserstrum, Yishay, Kornowski, Ran, Raanani, Pia, Leader, Avi, Pasvolsky, Oren, Iakobishvili, Zaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837153/
https://www.ncbi.nlm.nih.gov/pubmed/33530150
http://dx.doi.org/10.1186/s40959-015-0009-4
_version_ 1783642901828337664
author Wasserstrum, Yishay
Kornowski, Ran
Raanani, Pia
Leader, Avi
Pasvolsky, Oren
Iakobishvili, Zaza
author_facet Wasserstrum, Yishay
Kornowski, Ran
Raanani, Pia
Leader, Avi
Pasvolsky, Oren
Iakobishvili, Zaza
author_sort Wasserstrum, Yishay
collection PubMed
description New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.
format Online
Article
Text
id pubmed-7837153
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78371532021-01-27 Hypertension in cancer patients treated with anti-angiogenic based regimens Wasserstrum, Yishay Kornowski, Ran Raanani, Pia Leader, Avi Pasvolsky, Oren Iakobishvili, Zaza Cardiooncology Review New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors. BioMed Central 2015-12-07 /pmc/articles/PMC7837153/ /pubmed/33530150 http://dx.doi.org/10.1186/s40959-015-0009-4 Text en © Wasserstrum et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wasserstrum, Yishay
Kornowski, Ran
Raanani, Pia
Leader, Avi
Pasvolsky, Oren
Iakobishvili, Zaza
Hypertension in cancer patients treated with anti-angiogenic based regimens
title Hypertension in cancer patients treated with anti-angiogenic based regimens
title_full Hypertension in cancer patients treated with anti-angiogenic based regimens
title_fullStr Hypertension in cancer patients treated with anti-angiogenic based regimens
title_full_unstemmed Hypertension in cancer patients treated with anti-angiogenic based regimens
title_short Hypertension in cancer patients treated with anti-angiogenic based regimens
title_sort hypertension in cancer patients treated with anti-angiogenic based regimens
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837153/
https://www.ncbi.nlm.nih.gov/pubmed/33530150
http://dx.doi.org/10.1186/s40959-015-0009-4
work_keys_str_mv AT wasserstrumyishay hypertensionincancerpatientstreatedwithantiangiogenicbasedregimens
AT kornowskiran hypertensionincancerpatientstreatedwithantiangiogenicbasedregimens
AT raananipia hypertensionincancerpatientstreatedwithantiangiogenicbasedregimens
AT leaderavi hypertensionincancerpatientstreatedwithantiangiogenicbasedregimens
AT pasvolskyoren hypertensionincancerpatientstreatedwithantiangiogenicbasedregimens
AT iakobishvilizaza hypertensionincancerpatientstreatedwithantiangiogenicbasedregimens

Ejemplares similares